News and Trends 21 Mar 2023
Karuna Therapeutics sees positive schizophrenia trial results
Karuna Therapeutics, Inc. has announced positive topline results from its phase 3 EMERGENT-3 trial evaluating the efficacy, safety, and tolerability…
mental health issues
- Latest Posts
News and Trends 21 Mar 2023
Campbell Neurosciences creates saliva-based test for suicidal thoughts
Therapeutic Solutions International (TSOI) has announced that its spin-off biotech company, Campbell Neurosciences, Inc., obtained successful validation of its suicidal…
News and Trends 16 Feb 2023
Newron reports ‘striking’ schizophrenia study results
Newron Pharmaceuticals S.p.A. has announced what it says are ‘very exciting new results’ from the first 100 randomized patients who…
News and Trends 3 Jan 2023
Newron announces interim results from treatment-resistant schizophrenia trial
Newron Pharmaceuticals S.p.A. has announced what it says are “very compelling new results” from the first 100 enrolled patients to…
ADVERTISEMENT
News and Trends 15 Nov 2022
Potential new lead compounds for treatment of depression and anxiety disorders
Currently, various classes of drugs are available for the treatment of mental illnesses - such as depression and anxiety disorders.…
More News! 9 Nov 2022
Sensorium closes $30M deal to advance drug discovery engine
Sensorium Therapeutics, announced the closing of a $30 million series a financing to advance its initial asset, SENS-01, and Biodynamic…
News and Trends 1 Sep 2022
Study of injection to treat schizophrenia to begin after $3M payment received
A phase 3 clinical trial for an injection to treat patients with schizophrenia has been initiated after a $3 million…
News and Trends 23 Aug 2022
Freedom Biosciences exits stealth with $10.5M financing to develop mental health treatments
Freedom Biosciences, a U.S. clinical-stage biotech platform developing ketamine and psychedelic therapeutics, today emerged from stealth with $10.5 million in…
More News! 13 Jul 2022
Paradigm of treatment of mental health to be transformed by gut-brain development program
Building on a decade of research, a development program for next-generation probiotics and therapeutics to modulate gut microbiota and mental…
News and Trends 13 Jul 2022
Sanofi sells two portfolios of established products to Neuraxpharma
Two drugs portfolios with products to treat the central nervous system, pain and vascular disease have been bought by pharmaceutical…
ADVERTISEMENT
News and Trends 5 Jul 2022
Positive news from trial for drug to treat major depressive disorder
A company working on treatments for people with mental health issues has had positive feedback from the development program of…
